{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:06:39Z","timestamp":1788577599174,"version":"build-2803163510"},"reference-count":159,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":183,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI07\/0870"],"award-info":[{"award-number":["PI07\/0870"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00298"],"award-info":[{"award-number":["PI15\/00298"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/02057"],"award-info":[{"award-number":["PI16\/02057"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/00024"],"award-info":[{"award-number":["PI16\/00024"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00035"],"award-info":[{"award-number":["PI19\/00035"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00744"],"award-info":[{"award-number":["PI20\/00744"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00251"],"award-info":[{"award-number":["PI21\/00251"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01037"],"award-info":[{"award-number":["PI21\/01037"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00815"],"award-info":[{"award-number":["PI19\/00815"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DTS18\/00032"],"award-info":[{"award-number":["DTS18\/00032"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP20\/00122"],"award-info":[{"award-number":["CP20\/00122"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ISCIII-RETIC","award":["RD16\/0009"],"award-info":[{"award-number":["RD16\/0009"]}]},{"name":"ISCIII-RETIC","award":["RICORS2040"],"award-info":[{"award-number":["RICORS2040"]}]},{"name":"ISCIII-RETIC","award":["RD16\/0009\/0022"],"award-info":[{"award-number":["RD16\/0009\/0022"]}]},{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007757","name":"ACIISI","doi-asserted-by":"publisher","award":["TESIS2021010045"],"award-info":[{"award-number":["TESIS2021010045"]}],"id":[{"id":"10.13039\/501100007757","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007757","name":"ACIISI","doi-asserted-by":"publisher","award":["TESIS2018010110"],"award-info":[{"award-number":["TESIS2018010110"]}],"id":[{"id":"10.13039\/501100007757","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019170","name":"Cabildo de Tenerife","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019170","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TF Innova"},{"name":"Fondo de Desarrollo de Canarias"},{"name":"Marco Estrat\u00e9gico de Desarrollo Insular"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Diabetic kidney disease is one of the most frequent complications in patients with diabetes and constitutes a major cause of end-stage kidney disease. The prevalence of diabetic kidney disease continues to increase as a result of the growing epidemic of diabetes and obesity. Therefore, there is mounting urgency to design and optimize novel strategies and drugs that delay the progression of this pathology and contain this trend. The new approaches should go beyond the current therapy focussed on the control of traditional risk factors such as hyperglycaemia and hypertension. In this scenario, drug repurposing constitutes an economic and feasible approach based on the discovery of useful activities for old drugs. Pentoxifylline is a nonselective phosphodiesterase inhibitor currently indicated for peripheral artery disease. Clinical trials and meta-analyses have shown renoprotection secondary to anti-inflammatory and antifibrotic effects in diabetic patients treated with this old known drug, which makes pentoxifylline a candidate for repurposing in diabetic kidney disease.<\/jats:p>","DOI":"10.1093\/ckj\/sfac143","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T16:03:32Z","timestamp":1652976212000},"page":"2200-2213","source":"Crossref","is-referenced-by-count":18,"title":["Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease"],"prefix":"10.1093","volume":"15","author":[{"given":"Javier","family":"Donate-Correa","sequence":"first","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"},{"name":"GEENDIAB (Grupo Espa\u00f1ol para el estudio de la Nefropat\u00eda Diab\u00e9tica) , Sociedad Espa\u00f1ola de Nefrolog\u00eda, Santander , Spain"},{"name":"RICORS2040 (RD21\/0005\/0013), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Sanchez-Ni\u00f1o","sequence":"additional","affiliation":[{"name":"Departamento de Nefrolog\u00eda e Hipertensi\u00f3n, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz y Facultad de Medicina, Universidad Aut\u00f3noma de Madrid , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Gonz\u00e1lez-Luis","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"},{"name":"Escuela de doctorado, Universidad de La Laguna , La Laguna, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Ferri","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"},{"name":"Escuela de doctorado, Universidad de La Laguna , La Laguna, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mart\u00edn-Olivera","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"},{"name":"Escuela de doctorado, Universidad de La Laguna , La Laguna, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Mart\u00edn-N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"},{"name":"RICORS2040 (RD21\/0005\/0013), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Fernandez-Fernandez","sequence":"additional","affiliation":[{"name":"Departamento de Nefrolog\u00eda e Hipertensi\u00f3n, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz y Facultad de Medicina, Universidad Aut\u00f3noma de Madrid , Madrid , Spain"},{"name":"RICORS2040 (RD21\/0005\/0001), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor G","family":"Tagua","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mora-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"},{"name":"GEENDIAB (Grupo Espa\u00f1ol para el estudio de la Nefropat\u00eda Diab\u00e9tica) , Sociedad Espa\u00f1ola de Nefrolog\u00eda, Santander , Spain"},{"name":"RICORS2040 (RD21\/0005\/0013), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Departamento de Nefrolog\u00eda e Hipertensi\u00f3n, IIS-Fundaci\u00f3n Jim\u00e9nez D\u00edaz y Facultad de Medicina, Universidad Aut\u00f3noma de Madrid , Madrid , Spain"},{"name":"RICORS2040 (RD21\/0005\/0001), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-7474","authenticated-orcid":false,"given":"Juan F","family":"Navarro-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"},{"name":"GEENDIAB (Grupo Espa\u00f1ol para el estudio de la Nefropat\u00eda Diab\u00e9tica) , Sociedad Espa\u00f1ola de Nefrolog\u00eda, Santander , Spain"},{"name":"RICORS2040 (RD21\/0005\/0013), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Servicio de Nefrolog\u00eda, Hospital Universitario Nuestra Se\u00f1ora de Candelaria , Santa Cruz de Tenerife, Spain"},{"name":"Instituto de Tecnolog\u00edas Biom\u00e9dicas, Universidad de La Laguna , Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"2022111805392861600_bib1","author":"International Diabetes Federation","year":"2017","journal-title":"IDF Diabetes Atlas"},{"key":"2022111805392861600_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ki.2009.509","article-title":"Diabetic kidney disease: act now or pay later","volume":"77","author":"Atkins","year":"2010","journal-title":"Kidney Int"},{"key":"2022111805392861600_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1046\/j.1523-1755.2001.059002702.x","article-title":"Progression of diabetic nephropathy","volume":"59","author":"Hovind","year":"2001","journal-title":"Kidney Int"},{"key":"2022111805392861600_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2022111805392861600_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4093\/dmj.2020.0217","article-title":"Treatment of diabetic kidney disease: current and future","volume":"45","author":"Yamazaki","year":"2021","journal-title":"Diabetes Metab J"},{"key":"2022111805392861600_bib6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/ndt\/gfn603","article-title":"Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management Study (JDDM15)","volume":"24","author":"Yokoyama","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2022111805392861600_bib7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among us adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"2022111805392861600_bib8","first-page":"1199","volume-title":"Oxford Textbook of Clinical Nephrology","author":"Gnudi","year":"2016","edition":"4th ed."},{"key":"2022111805392861600_bib9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0272-6386(99)70035-1","article-title":"End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions","volume":"34","author":"Ritz","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2022111805392861600_bib10","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1523-1755.2005.09403.x","article-title":"The epidemiology of chronic kidney disease","volume":"67","author":"Atkins","year":"2005","journal-title":"Kidney Int"},{"key":"2022111805392861600_bib11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"2022111805392861600_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrendo.2012.125","article-title":"Diabetes: treating diabetic nephropathy-still an unresolved issue","volume":"8","author":"Cooper","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022111805392861600_bib14","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s001250100000","article-title":"Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy","volume":"44","author":"Cooper","year":"2001","journal-title":"Diabetologia"},{"key":"2022111805392861600_bib15","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1681\/ASN.2006121362","article-title":"Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism","volume":"18","author":"Gnudi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib16","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"2022111805392861600_bib17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2022111805392861600_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14789450.2018.1545577","article-title":"Advances in understanding the role of angiotensin-regulated proteins in kidney diseases","volume":"16","author":"Sanz","year":"2019","journal-title":"Expert Rev Proteomics"},{"key":"2022111805392861600_bib19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jdiacomp.2015.11.003","article-title":"Elevated baseline glomerular filtration rate (GFR) is independently associated with a more rapid decline in renal function of patients with type 1 diabetes","volume":"30","author":"Thomson","year":"2016","journal-title":"J Diabetes Complications"},{"key":"2022111805392861600_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/hy09t1.094234","article-title":"Angiotensin II and renal fibrosis","volume":"38","author":"Mezzano","year":"2001","journal-title":"Hypertension"},{"key":"2022111805392861600_bib21","doi-asserted-by":"crossref","first-page":"F360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"key":"2022111805392861600_bib22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (The ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"2022111805392861600_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/2042098615589905","article-title":"Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function","volume":"6","author":"Esteras","year":"2015","journal-title":"Ther Adv Drug Saf"},{"key":"2022111805392861600_bib24","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib25","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1681\/ASN.2011040378","article-title":"Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy","volume":"23","author":"Packham","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2 diabetic nephropathy","volume":"23","author":"Lewis","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib29","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib30","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib31","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nrendo.2010.212","article-title":"Oxidative stress in early diabetic nephropathy: fueling the fire","volume":"7","author":"Singh","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"2022111805392861600_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneph.2011.51","article-title":"Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy","volume":"7","author":"Navarro-Gonzalez","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2022111805392861600_bib34","doi-asserted-by":"crossref","first-page":"696542","DOI":"10.3389\/fcell.2021.696542","article-title":"Signaling pathways involved in diabetic renal fibrosis","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2022111805392861600_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.kint.2017.12.026","article-title":"Drug repurposing in kidney disease","volume":"94","author":"Panchapakesan","year":"2018","journal-title":"Kidney Int"},{"key":"2022111805392861600_bib36","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"2022111805392861600_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomized clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022111805392861600_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/ndt\/gfy407","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"34","author":"Sarafidis","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2022111805392861600_bib40","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"2022111805392861600_bib41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/13543784.2016.1196184","article-title":"Targeting inflammation in diabetic kidney disease: early clinical trials","volume":"25","author":"Perez-Gomez","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"2022111805392861600_bib42","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin Ther"},{"key":"2022111805392861600_bib43","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am J Cardiol"},{"key":"2022111805392861600_bib44","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2022111805392861600_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease","volume":"35","author":"Wan","year":"2021","journal-title":"J Hum Hypertens"},{"key":"2022111805392861600_bib46","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib47","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1507\/endocrj.K10E-382","article-title":"Sitagliptin reduces albuminuria in patients with type 2 diabetes","volume":"58","author":"Hattori","year":"2011","journal-title":"Endocr J"},{"key":"2022111805392861600_bib49","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/dmrr.2437","article-title":"Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE)-Receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes","volume":"29","author":"Sakata","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"2022111805392861600_bib50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib51","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib52","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib53","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and Glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"2022111805392861600_bib54","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022111805392861600_bib55","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib56","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022111805392861600_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2022111805392861600_bib58","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes Obesity Metab"},{"key":"2022111805392861600_bib59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"2022111805392861600_bib60","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol"},{"key":"2022111805392861600_bib61","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s00125-008-1224-4","article-title":"High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study","volume":"52","author":"Rabbani","year":"2009","journal-title":"Diabetologia"},{"key":"2022111805392861600_bib62","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000075627","article-title":"Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy","volume":"24","author":"Bolton","year":"2004","journal-title":"Am J Nephrol"},{"key":"2022111805392861600_bib63","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.2337\/dc09-2241","article-title":"A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy","volume":"33","author":"Alkhalaf","year":"2010","journal-title":"Diabetes Care"},{"key":"2022111805392861600_bib64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03256811","article-title":"Repurposing strategies for therapeutics","volume":"24","author":"Sleigh","year":"2010","journal-title":"Pharm Med"},{"key":"2022111805392861600_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2022111805392861600_bib66","doi-asserted-by":"crossref","first-page":"118275","DOI":"10.1016\/j.lfs.2020.118275","article-title":"Utilizing drug repurposing against COVID-19\u2013efficacy, limitations, and challenges","volume":"259","author":"Parvathaneni","year":"2020","journal-title":"Life Sci"},{"key":"2022111805392861600_bib67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/138920106779116919","article-title":"Thalidomide in multiple myeloma","volume":"7","author":"Moehler","year":"2006","journal-title":"Curr Pharm Biotechnol"},{"key":"2022111805392861600_bib68","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1073\/pnas.0500815102","article-title":"Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress","volume":"102","author":"Dinkova-Kostova","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022111805392861600_bib69","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000327599","article-title":"Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD","volume":"33","author":"Pergola","year":"2011","journal-title":"Am J Nephrol"},{"key":"2022111805392861600_bib70","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"2022111805392861600_bib71","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1159\/000362906","article-title":"Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"39","author":"Chin","year":"2014","journal-title":"Am J Nephrol"},{"key":"2022111805392861600_bib72","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","article-title":"Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"20","author":"Chin","year":"2014","journal-title":"J Card Fail"},{"key":"2022111805392861600_bib73","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ekir.2020.03.030","article-title":"Randomized clinical trial on the effect of bardoxolone methyl on GFR in diabetic kidney disease patients (TSUBAKI study)","volume":"5","author":"Nangaku","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2022111805392861600_bib74","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomized trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022111805392861600_bib75","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2022111805392861600_bib76","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2022111805392861600_bib77","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.2003.04.176","article-title":"Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial","volume":"21","author":"Carducci","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022111805392861600_bib78","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"2022111805392861600_bib79","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/01.HYP.31.1.397","article-title":"Endothelin-A receptor antagonism attenuates the hypertension and renal injury in dahl salt-sensitive rats","volume":"31","author":"Kassab","year":"1998","journal-title":"Hypertension"},{"key":"2022111805392861600_bib80","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib81","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib82","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomized, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"2022111805392861600_bib83","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","article-title":"Clinical efficacy of the selective endothelin a receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"Andress","year":"2012","journal-title":"Life Sci"},{"key":"2022111805392861600_bib84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib85","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc18-0078","article-title":"Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease","volume":"41","author":"Navarro-Gonz\u00e1lez","year":"2018","journal-title":"Diabetes Care"},{"key":"2022111805392861600_bib86","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/jcm8030287","article-title":"Pentoxifylline for renal protection in diabetic kidney disease. A model of old drugs for new horizons","volume":"8","author":"Donate-Correa","year":"2019","journal-title":"J Clin Med"},{"key":"2022111805392861600_bib87","author":"US Food & Drug Administration","journal-title":"Drugs-FDA: FDA Approved Drug Products"},{"key":"2022111805392861600_bib88","first-page":"7","article-title":"Treatment of intermittent claudication with pentoxifylline: a 12 month, randomized trial\u2013walking distance and microcirculation","volume":"53","author":"De Sanctis","year":"2002","journal-title":"Angiology"},{"key":"2022111805392861600_bib89","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/j.1875-9114.1984.tb03380.x","article-title":"Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects","volume":"4","author":"Aviado","year":"1984","journal-title":"Pharmacotherapy"},{"key":"2022111805392861600_bib90","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/000331978403500703","article-title":"Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication","volume":"35","author":"Aviado","year":"1984","journal-title":"Angiology"},{"key":"2022111805392861600_bib91","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1007\/s13300-021-01168-x","article-title":"Are the protean effects of pentoxifylline in the therapy of diabetes and its complications still relevant?","volume":"12","author":"Bell","year":"2021","journal-title":"Diabetes Ther"},{"key":"2022111805392861600_bib92","first-page":"3","article-title":"Effect of trental on indices kidney function in diabetes mellitus","volume":"28","author":"Blagosklonnaia","year":"1982","journal-title":"Probl Endokrinol"},{"key":"2022111805392861600_bib93","first-page":"192","article-title":"Pentoxifylline suppression of tumor necrosis factor gene transcription","volume":"110","author":"Doherty","year":"1991","journal-title":"Surgery"},{"key":"2022111805392861600_bib94","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s12325-017-0547-2","article-title":"Repurposing pentoxifylline for the treatment of fibrosis: an overview","volume":"34","author":"Wen","year":"2017","journal-title":"Adv Ther"},{"key":"2022111805392861600_bib95","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(99)70182-4","article-title":"Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration","volume":"33","author":"Navarro","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2022111805392861600_bib96","doi-asserted-by":"crossref","first-page":"c73","DOI":"10.1159\/000083417","article-title":"Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus","volume":"99","author":"Aminorroaya","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"2022111805392861600_bib97","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5414\/CNP64091","article-title":"Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients-A randomized, equivalent trial","volume":"64","author":"Rodr\u00edguez-Mor\u00e1n","year":"2005","journal-title":"Clin Nephrol"},{"key":"2022111805392861600_bib98","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1681\/ASN.2005010001","article-title":"Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial","volume":"16","author":"Navarro","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib99","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5414\/CNP66003","article-title":"Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial","volume":"66","author":"Rodr\u00edguez-Mor\u00e1n","year":"2006","journal-title":"Clin Nephrol"},{"key":"2022111805392861600_bib100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40261-013-0057-1","article-title":"Effect of add-on pentoxifylline on proteinuria in membranous glomerulonephritis: a 6-month placebo-controlled trial","volume":"33","author":"Badri","year":"2013","journal-title":"Clin Drug Investig"},{"key":"2022111805392861600_bib101","first-page":"410","article-title":"Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin converting enzyme inhibitor and an angiotensin receptor blocker?","volume":"20","author":"Diskin","year":"2007","journal-title":"J Nephrol"},{"key":"2022111805392861600_bib102","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1053\/j.ajkd.2008.11.026","article-title":"Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial","volume":"53","author":"Perkins","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2022111805392861600_bib103","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5301\/jn.5000077","article-title":"Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a ran-domized trial","volume":"25","author":"Goicoechea","year":"2012","journal-title":"J Nephrol"},{"key":"2022111805392861600_bib104","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/j.ajkd.2008.05.012","article-title":"Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12 month randomized trial","volume":"52","author":"Lin","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2022111805392861600_bib105","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/sj.ki.5000302","article-title":"Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases","volume":"69","author":"Chen","year":"2006","journal-title":"Kidney Int"},{"key":"2022111805392861600_bib106","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jfma.2014.01.002","article-title":"Renoprotective effect of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in advanced chronic kidney disease","volume":"113","author":"Chen","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"2022111805392861600_bib107","doi-asserted-by":"crossref","first-page":"157","DOI":"10.5414\/CNP67157","article-title":"Effect of pentoxifylline on graft function of renal transplant recipients complicated with chronic allograft nephropathy","volume":"67","author":"Shu","year":"2007","journal-title":"Clin Nephrol"},{"key":"2022111805392861600_bib108","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.172.1.391","article-title":"Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin\/tumor necrosis factor synthesis at separate points in the signaling pathway","volume":"172","author":"Han","year":"1990","journal-title":"J Exp Med"},{"key":"2022111805392861600_bib109","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/ndt\/gfh127","article-title":"Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats","volume":"19","author":"Chen","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2022111805392861600_bib110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000079121","article-title":"Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats","volume":"24","author":"DiPetrillo","year":"2004","journal-title":"Am J Nephrol"},{"key":"2022111805392861600_bib111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12950-015-0080-5","article-title":"Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase","volume":"12","author":"Garcia","year":"2015","journal-title":"J Inflamm (Lond)"},{"key":"2022111805392861600_bib112","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000368331","article-title":"Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny","volume":"129","author":"Gentile","year":"2015","journal-title":"Nephron"},{"key":"2022111805392861600_bib113","first-page":"R1412","article-title":"Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats","volume":"275","author":"Voisin","year":"1998","journal-title":"Am J Physiol Content"},{"key":"2022111805392861600_bib114","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/ndt\/15.10.1535","article-title":"Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts","volume":"15","author":"Strutz","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"2022111805392861600_bib115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1043-6618(03)00002-1","article-title":"The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat","volume":"47","author":"Abdel-Salam","year":"2003","journal-title":"Pharmacol Res"},{"key":"2022111805392861600_bib116","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/154386090897974","article-title":"Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat","volume":"5","author":"D\u00e1vila-Esqueda","year":"2004","journal-title":"Exp Diabesity Res"},{"key":"2022111805392861600_bib117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1681\/ASN.2007091048","article-title":"The role of inflammatory cytokines in diabetic nephropathy","volume":"19","author":"Navarro-Gonz\u00e1lez","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib118","doi-asserted-by":"crossref","first-page":"948417","DOI":"10.1155\/2015\/948417","article-title":"Inflammatory cytokines in diabetic nephropathy","volume":"2015","author":"Donate-Correa","year":"2015","journal-title":"J Diabetes Res"},{"key":"2022111805392861600_bib119","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.phrs.2016.03.001","article-title":"Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta-analysis","volume":"107","author":"Leporini","year":"2016","journal-title":"Pharmacol Res"},{"key":"2022111805392861600_bib120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0300060516663094","article-title":"Pentoxifylline plus ACEIs\/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis","volume":"45","author":"Liu","year":"2017","journal-title":"J Int Med Res"},{"key":"2022111805392861600_bib121","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/cpt.173","article-title":"Pentoxifylline decreases dialysis risk in patients with advanced chronic kidney disease","volume":"98","author":"Wu","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2022111805392861600_bib122","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","article-title":"Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents","volume":"109","author":"Lugnier","year":"2006","journal-title":"Pharmacol Ther"},{"key":"2022111805392861600_bib123","first-page":"38","article-title":"Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease","volume":"232","author":"Cheng","year":"2007","journal-title":"Exp Biol Med (Maywood)"},{"key":"2022111805392861600_bib124","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/mol.64.4.811","article-title":"Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking Akt membrane translocation","volume":"64","author":"Lin","year":"2003","journal-title":"Mol Pharmacol"},{"key":"2022111805392861600_bib125","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1681\/ASN.2005040435","article-title":"Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3\/4-activated transcription and profibrogenic effects of connective tissue growth factor","volume":"16","author":"Lin","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib126","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1124\/jpet.103.062620","article-title":"Dual regulation of tumor necrosis fac-tor-alpha-induced CCL2\/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kappaB and activator protein-1: modulation by type III phosphodiesterase inhibition","volume":"309","author":"Chen","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"2022111805392861600_bib127","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2165\/00003495-198734010-00003","article-title":"Pentoxifylline: a review of its pharmacodynamics and pharmacokinetic properties and its therapeutic efficacy","volume":"34","author":"Ward","year":"1987","journal-title":"Drugs"},{"key":"2022111805392861600_bib128","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.trsl.2014.07.010","article-title":"Therapeutic targets for treating fibrotic kidney diseases","volume":"165","author":"Lee","year":"2015","journal-title":"Transl Res"},{"key":"2022111805392861600_bib129","doi-asserted-by":"crossref","first-page":"697010","DOI":"10.1155\/2015\/697010","article-title":"Diabetic kidney disease: pathophysiology and therapeutic targets","volume":"2015","author":"Toth-Manikowski","year":"2015","journal-title":"J Diabetes Res"},{"key":"2022111805392861600_bib130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1006\/jmcc.1998.0910","article-title":"Pentoxifylline inhibits PDGF-induced proliferation of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells","volume":"31","author":"Chen","year":"1999","journal-title":"J Mol Cell Cardiol"},{"key":"2022111805392861600_bib131","first-page":"1179","article-title":"Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. In phosphodiesterase inhibitors","volume":"8","author":"Tenor","year":"1995","journal-title":"Eur Respir J"},{"key":"2022111805392861600_bib132","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/mol.56.1.170","article-title":"Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils","volume":"56","author":"Wang","year":"1999","journal-title":"Mol Pharmacol"},{"key":"2022111805392861600_bib133","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"2022111805392861600_bib134","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.atherosclerosis.2006.11.032","article-title":"Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease\u2014A randomized placebo-controlled study","volume":"196","author":"Fernandes","year":"2008","journal-title":"Atherosclerosis"},{"key":"2022111805392861600_bib135","first-page":"23","article-title":"Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients","volume":"18","author":"Mohammadpour","year":"2014","journal-title":"Iran Biomed J"},{"key":"2022111805392861600_bib136","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1097\/01.ASN.0000131523.17045.56","article-title":"Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure","volume":"15","author":"Cooper","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2022111805392861600_bib137","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2008.01.025","article-title":"The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis","volume":"52","author":"McCormick","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2022111805392861600_bib138","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11255-015-0968-2","article-title":"Efficacy and safety of combining pentoxifylline with angiotensin converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis","volume":"47","author":"Tian","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"2022111805392861600_bib139","doi-asserted-by":"crossref","first-page":"F1329","DOI":"10.1152\/ajprenal.00487.2016","article-title":"Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms","volume":"311","author":"Ruiz-Andres","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022111805392861600_bib140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the mouse klotho gene leads to a syndrome resembling ageing","volume":"390","author":"Kuro-o","year":"1997","journal-title":"Nature"},{"key":"2022111805392861600_bib141","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2011.08.850","article-title":"Expression of FGF23\/KLOTHO system in human vascular tissue","volume":"165","author":"Donate-Correa","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022111805392861600_bib142","doi-asserted-by":"crossref","first-page":"e94375","DOI":"10.1172\/jci.insight.94375","article-title":"Human alternative Klotho mRNA is a nonsense-mediated mRNA decay target inefficiently spliced in renal disease","volume":"2","author":"Mencke","year":"2017","journal-title":"JCI Insight"},{"key":"2022111805392861600_bib143","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cell.2017.10.025","article-title":"In vivo target gene activation via CRISPR\/Cas9-mediated trans-epigenetic modulation","volume":"171","author":"Liao","year":"2017","journal-title":"Cell"},{"key":"2022111805392861600_bib144","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2014.01.024","article-title":"Association of plasma soluble \u03b1-klotho with pro-endothelin-1 in patients with type 2 diabetes","volume":"233","author":"Liu","year":"2014","journal-title":"Atherosclerosis"},{"key":"2022111805392861600_bib145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diabres.2014.08.026","article-title":"The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin","volume":"106","author":"Wu","year":"2014","journal-title":"Diabetes Res Clin Pr"},{"key":"2022111805392861600_bib146","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/ki.2011.423","article-title":"Decreased renal \u03b1-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion","volume":"81","author":"Asai","year":"2012","journal-title":"Kidney Int"},{"key":"2022111805392861600_bib147","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jdiacomp.2016.03.006","article-title":"Decreased plasma \u03b1-Klotho predict progression of nephropathy with type 2 diabetic patients","volume":"30","author":"Kim","year":"2016","journal-title":"J Diabetes Complicat"},{"key":"2022111805392861600_bib148","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1681\/ASN.2010101073","article-title":"The inflammatory cytokines TWEAK and TNF\u03b1 reduce renal klotho expression through NF-\u03baB","volume":"22","author":"Moreno","year":"2011","journal-title":"J. Am Soc Nephrol"},{"key":"2022111805392861600_bib149","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.2337\/db10-1262","article-title":"Klotho depletion contributes to increased inflammation in kidney of the db\/db mouse model of diabetes via RelA (serine)536 phosphorylation","volume":"60","author":"Zhao","year":"2011","journal-title":"Diabetes"},{"key":"2022111805392861600_bib150","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.18632\/aging.102734","article-title":"Association between serum levels of Klotho and inflammatory cytokines in cardiovascular disease: a case-control study","volume":"12","author":"Mart\u00edn-N\u00fa\u00f1ez","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2022111805392861600_bib151","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/ckj\/sfaa200","article-title":"Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study","volume":"14","author":"Kovesdy","year":"2020","journal-title":"Clin Kidney J"},{"key":"2022111805392861600_bib152","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12325-019-01180-5","article-title":"Albuminuria downregulation of the anti-aging factor klotho: the missing link potentially explaining the association of pathological albuminuria with premature death","volume":"37","author":"Fern\u00e1ndez-Fern\u00e1ndez","year":"2020","journal-title":"Adv Ther"},{"key":"2022111805392861600_bib153","doi-asserted-by":"crossref","first-page":"e0261797","DOI":"10.1371\/journal.pone.0261797","article-title":"Pentoxifylline-induced protein expression change in RAW 264.7 cells as determined by immunoprecipitation-based high performance liquid chromatography","volume":"17","author":"Seo","year":"2022","journal-title":"PLoS One"},{"key":"2022111805392861600_bib154","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ckj\/sfab170","article-title":"RICORS2040: the need for collaborative research in chronic kidney disease","volume":"15","author":"Ortiz","year":"2021","journal-title":"Clin Kidney J"},{"key":"2022111805392861600_bib155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12882-018-0942-1","article-title":"Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus","volume":"19","author":"Go","year":"2018","journal-title":"BMC Nephrol"},{"key":"2022111805392861600_bib156","doi-asserted-by":"crossref","first-page":"13521","DOI":"10.1038\/s41598-021-92753-4","article-title":"The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment","volume":"11","author":"Fang","year":"2021","journal-title":"Sci Rep"},{"key":"2022111805392861600_bib157","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13904","article-title":"Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study","volume":"16","author":"Ocak","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2022111805392861600_bib158","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/SLA.0000000000000244","article-title":"The risk of perioperative bleeding in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"258","author":"Acedillo","year":"2013","journal-title":"Ann Surg"},{"key":"2022111805392861600_bib159","doi-asserted-by":"crossref","first-page":"e053019","DOI":"10.1136\/bmjopen-2021-053019","article-title":"Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial","volume":"11","author":"Leehey","year":"2021","journal-title":"BMJ Open"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfac143\/45192700\/sfac143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/12\/2200\/47107557\/sfac143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/12\/2200\/47107557\/sfac143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T05:42:59Z","timestamp":1668750179000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/12\/2200\/6589427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":159,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,5,19]]},"published-print":{"date-parts":[[2022,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfac143","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,5,19]]}}}